


PHARMACEUTICAL 2020

Savara Inc Rank 220 of 362









PHARMACEUTICAL 2020



Savara Inc Rank 220 of 362

The relative strengths and weaknesses of Savara Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Savara Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 186% points. The greatest weakness of Savara Inc is the variable Net Income, reducing the Economic Capital Ratio by 139% points.

The company's Economic Capital Ratio, given in the ranking table, is -241%, being 62% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	124,067
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	10,880
Liabilities, Non-Current	513
Other Assets	11,784
Other Compr. Net Income	-217
Other Expenses	27,163
Other Liabilities	23,112
Other Net Income	852
Property and Equipment	352
Research and Development	38,781
Revenues	0
Selling, General and Administrative Expense	13,081

Output Variable	Value in 1000 USD
Assets	136,203
Liabilities	34,505
Expenses	79,025
Stockholders Equity	101,698
Net Income	-78,173
Comprehensive Net Income	-78,282
Economic Capital Ratio	-241%

